A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

  • Fujise, Kenichi (PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/12 → 1/31/17

Funding

  • Novartis Pharmaceuticals Corporation: $90,620.00